From: Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
Risk group
% of births
Births in 2015
Vaccination Cost USD
CHD
0.03%
50
314,057
CLD
0.12%
217
1,360,912
<29
0.42%
753
4,731,498
29–32
0.88%
1570
9,862,078
33–36
6.13%
10,956
68,814,325
No risk
92.42%
165,177
1,037,499,916